Home / FlashMed

FlashMed

Titolo Detection of Chronic Kidney Disease With Creatinine, Cystatin C, and Urine Albumin-to-Creatinine Ratio and Association With Progression to End-Stage Renal Disease and Mortality
Autore Carmen A. Peralta, MD, MAS; Michael G. Shlipak, MD, MPH; Suzanne Judd, PhD; Mary Cushman, MD; William McClellan, MD, MPH; Neil A. Zakai, MD; Monika M. Safford, MD; Xiao Zhang, PhD; Paul Muntner, PhD; David Warnock, MD
Referenza JAMA 2011; 305 (15): 1545-1552
Contenuto Abstract (abbreviated) Context A triple-marker approach for chronic kidney disease (CKD) evaluation has not been well studied. Objective To evaluate whether combining creatinine, cystatin C, and urine albumin-to-creatinine ratio (ACR) would improve identification of risks associated with CKD compared with creatinine alone. Design, Setting, and Participants Prospective cohort study involving 26 643 US adults enrolled in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study from January 2003 to June 2010. Participants were categorized into 8 groups defined by estimated glomerular filtration rate (GFR) determined by creatinine and by cystatin C of either <60 or ≥60 mL/min/1.73 m2 and ACR of either <30 or ≥30 mg/g. Conclusion Adding cystatin C to the combination of creatinine and ACR measures improved the predictive accuracy for all-cause mortality and end-stage renal disease.
Data 25.01.2012
 
Maggiori informazioni   
Lista completa